Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2019 16:05 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four...
March 04, 2019 16:35 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018

EMERYVILLE, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended...
February 20, 2019 16:50 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Present at Two Upcoming Investor Conferences

EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
February 20, 2019 16:49 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019

EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2018 financial results on...
February 08, 2019 18:49 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three...
January 10, 2019 16:30 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Jan. 10, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new...
January 06, 2019 11:38 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019

-- GOCOVRI preliminary net sales of approximately $13.3 million for the fourth quarter of 2018 and approximately $34 million for the year -- -- Preliminary total prescriptions of approximately 5,700...
December 18, 2018 16:30 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™

EMERYVILLE, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
November 09, 2018 13:49 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Present at Three November Investor Conferences

EMERYVILLE, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
November 01, 2018 16:01 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Third Quarter 2018 Financial Results

GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) --...